Latest results show sustained and further improvement in vision at 60 and 120 days in first patient cohort of Phase 2a study of hRPC cell therapy in retinitis pigmentosa

26 April 2019: ReNeuron Group plc (AIM: RENE), a global leader in the development of cell-based therapeutics, is pleased to announce updated positive preliminary data in the Company’s ongoing Phase 1/2a clinical trial of its human retinal progenitor cell (hRPC) therapy candidate in the blindness-causing disease, retinitis pigmentosa (RP).  All three subjects in the first cohort of the Phase 2a element of the study have demonstrated a sustained and further improvement in vision compared with their pre-treatment baseline.

Read more…